Alison W. Loren MD, MSCE Blood & Marrow Transplantation Abramson Cancer Center University of Pennsylvania Pennsylvania, PA, USA
Catherine E. Lucid ACNP‐BC, MSN Hematology and Stem Cell Transplantation Section Division of Hematology/Oncology Vanderbilt University Medical Center Nashville, TN, USA
Kristy Luke NP Section of Bone Marrow Transplant and Cellular Therapy Rush University Medical Center Chicago, IL, USA
Enrico Maffini MD Department of Oncology AOU Città della Salute e della Scienza di Torino Department of Molecular Biotechnology and Health Sciences University of Torino, Torino, Italy
Navneet S. Majhail MD, MS Blood and Marrow Transplant Program Cleveland Clinic Taussig Cancer Institute Cleveland, OH, USA
Leslee Matheny MD Division of Diabetes, Endocrinology & Metabolism Vanderbilt University Medical Center Nashville, TN, USA
Juliana Matthews MD Division of Diabetes, Endocrinology & Metabolism Vanderbilt University Medical Center Nashville, TN, USA
David Michonneau MD, PhD Hematology Transplantation APHP Hospital Saint Louis and Université de Paris; Université de Paris & INSERM U976 Paris, France
Sandra A. Mitchell PhD, CRNP, AOCN Outcomes Research Branch Healthcare Delivery Research Program Division of Cancer Control and Population Sciences National Cancer Institute Bethesda, MD, USA
Emilee Moeke RN Section of Bone Marrow Transplant and Cellular Therapy Rush University Medical Center Chicago, IL, USA
Angela Moreschi Woods MSN APRN ACNP‐BC National Marrow Donor Program Minneapolis, MN, USA
Ibrahim N. Muhsen MD Department of Medicine Houston Methodist Hospital and Weill Cornell Medical College Houston, TX, USA
Jeanne Murphy PhD, CNM, FACNM The George Washington University Washington, DC, USA
Sunita Nathan MD Section of Bone Marrow Transplant and Cellular Therapy Rush University Medical Center Chicago, IL, USA
Shinichiro Okamoto MD, PhD Division of Hematology Department of Medicine Keio University School of Medicine Tokyo, Japan
Attilio Olivieri MD Clinica di Ematologia Department of molecular and clinical sciences Ancona University Ancona, Italy
Steven Pavletic MD Immune Deficiency Cellular Therapy Program Graft‐versus‐Host and Late Effects Section Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda, MD, USA
Rachel Phelan Center of International Blood and Marrow Transplant Research; Department of Medicine Medical College of Wisconsin Milwaukee, WI, USA
Jakob R. Passweg MD Division of Hematology University Hospital Basel Basel, Switzerland
J. Douglas Rizzo MD, MS Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research Milwaukee, WI, USA
Montserrat Rovira MD, PhD Hospital Clinic Hematopoietic Cell Transplantation Program Barcelona, Spain
Alicia Rovó MD Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern, Switzerland
Nina Salooja FRCPath MD Department of Medicine Imperial College London Hammersmith Hospital London, UK
Insara Jaffer Sathick MD Renal Service, Division of Medicine Memorial Sloan Kettering Cancer Center New York, NY, USA
Bipin N. Savani MD Long Term Transplant Clinic (LTTC), Hematology, Stem Cell Transplantation and Cellular Therapy Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA
Angela Scherwath PhD Department and Outpatient Clinic of Medical Psychology University Medical Center Hamburg – Eppendorf Hamburg, Germany
Hélène Schoemans MD, PhD Department of Hematology University Hospitals Leuven and KU Leuven Leuven, Belgium
Dana Shanis MD, FACOG VHealth & Wellness Philadelphia, PA, USA
Bronwen E. Shaw MD, PhD Center of International Blood and Marrow Transplant Research; Department of Medicine Medical College of Wisconsin Milwaukee, WI, USA
Gérard Socié MD, PhD Hematology TransplantationAPHP Hospital Saint Louis and Université de Paris; Université de Paris & INSERM U976 Paris, France
Ayman O. Soubani MD Division of Pulmonary, Critical Care and Sleep Medicine Wayne State University School of Medicine Detroit, MI, USA
Katrina M. Stokes MSSW LCSW Tennessee Valley Healthcare System Nashville, TN, USA
Pamela Stratton MD Office of the Clinical Director National Institute for Neurological Disorders and Stroke Bethesda, MD, USA
Aurélien Sutra del Galy MD Hematology Transplantation APHP Hospital Saint Louis and Université de Paris; Université de Paris & INSERM U976 Paris; France
Sarah Thilges PhD Section of Psychosocial Oncology Loyola University Medical Center Maywood, IL, USA
André Tichelli MD Division of Hematology University Hospital Basel Basel, Switzerland
Mihkaila Wickline MD Seattle Cancer Care Alliance Fred Hutchinson Cancer Research Center Seattle, WA, USA
Lori Wiener, PhD, DCSW, LCSW‐C Psychosocial Support and Research Program Center for Cancer Research Pediatric Oncology Branch NIH Bethesda, MD, USA
John R. Wingard MD Division of Hematology & Oncology University of Florida College of Medicine Gainesville, FL, USA
CHAPTER 1 Introduction to long‐term survivorship after hematopoietic cell transplantation
Bipin N. Savani1 and André Tichelli2
1 Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
2 Division of Hematology, University Hospital Basel, Basel, Switzerland
Background
Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT and now HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients [1,2‐4].
The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft‐versus‐host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long‐term free